Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Total Current Liabilities

Last Annual Value

61.36M

3-Year CAGR

103%

5-Year CAGR

48%

10-Year CAGR

34%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Total Current Liabilities

SLNO · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
61.36M
74.7%50.3%43.1% 
384.00M
11.0%16.2%20.3%
50.62M
-0.3%12.0%-25.1%
CELC logo
Celcuity Inc.
NASDAQ:CELC
44.15M
46.0%77.5%58.4%
59.77M
56.0%9.2%N/A
76.67M
58.8%54.3%28.0%
27.91M
10.7%N/AN/A
205.80M
33.2%37.0%N/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01